CNS Pharmaceuticals Inc
$ 5.31
-13.94%
29 Dec - close price
- Market Cap 3,827,200 USD
- Current Price $ 5.31
- High / Low $ 6.09 / 5.30
- Stock P/E 0.01
- Book Value 17.25
- EPS 776.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.86 %
- ROE -1.97 %
- 52 Week High 114.00
- 52 Week Low 4.93
About
CNS Pharmaceuticals, Inc. is a Houston-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeted at brain and central nervous system tumors. The company is advancing its lead candidate, which seeks to address significant unmet medical needs in oncology, particularly in the challenging domain of neuro-oncology. Through a robust scientific foundation and strategic partnerships, CNS Pharmaceuticals aims to enhance patient outcomes while navigating the complexities of brain cancer treatment. This pioneering approach positions the company as a significant contender in the evolving field of neuro-oncology therapeutics, underscoring its commitment to improving the lives of patients affected by these devastating conditions.
Analyst Target Price
$20.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-09-30 | 2025-08-13 | 2025-04-30 | 2025-03-31 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-14 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -5.76 | -6.42 | -2.2471 | -37.33 | -0.2527 | -6.7192 | -0.4068 | -28622.9609 | -2.7 | -1.0371 | -2.5869 | -3.8211 |
| Estimated EPS | -6.63 | -9.6 | -2 | -7.33 | -0.1 | None | None | None | -2.4 | None | None | -2.4 |
| Surprise | 0.87 | 3.18 | -0.2471 | -30 | -0.1527 | 0 | 0 | 0 | -0.3 | 0 | 0 | -1.4211 |
| Surprise Percentage | 13.1222% | 33.125% | -12.355% | -409.2769% | -152.7% | None% | None% | None% | -12.5% | None% | None% | -59.2125% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CNSP
2025-12-19 21:09:58
CNS Pharmaceuticals has appointed Rami Levin as its new CEO and President, effective January 1, 2026, replacing John Climaco who resigned. Levin brings extensive biopharmaceutical leadership experience, while the company faces financial challenges despite a "Buy" rating from some analysts. TipRanks' AI Analyst, Spark, assesses CNSP as "Underperform" due to profitability concerns, although technical indicators suggest potential stabilization.
2025-12-18 22:09:13
CNS Pharmaceuticals has appointed Rami Levin as its new Chief Executive Officer and President, effective January 1, 2026, succeeding John Climaco who resigned on December 16, 2025. Levin will also join the company's Board of Directors. The company also recently approved an amendment to increase the total number of authorized shares of common and preferred stock.
2025-12-17 23:09:11
CNS Pharmaceuticals (NASDAQ: CNSP) announced that Rami Levin, MBA, is appointed President and CEO, effective January 1, 2026, replacing John Climaco. Levin brings extensive experience in oncology, neurology, and rare diseases, poised to advance the company's pipeline. CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for brain and central nervous system cancers.
2025-12-17 23:09:08
CNS Pharmaceuticals appointed Rami Levin, MBA, as its new President and CEO, effective January 1, 2026, replacing John Climaco. Levin brings nearly three decades of global leadership experience in oncology, neurology, and rare diseases, with a strong background in advancing clinical programs and strategic turnarounds. This appointment is expected to facilitate the advancement of CNS Pharmaceuticals' pipeline and support its next phase of development.
2025-12-17 23:09:08
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) announced that John Climaco has stepped down as CEO and Rami Levin, MBA, an industry veteran with nearly 30 years of global leadership experience in oncology, neurology, and rare diseases, has been appointed as President & Chief Executive Officer, effective January 1, 2026. Levin's expertise includes scaling organizations, advancing clinical programs, and driving value creation, having previously held senior roles at Saniosana and IMStem Biotechnology. The company looks forward to Levin leveraging his scientific depth, commercial execution, and capital markets expertise to lead CNS through its next phase of growth.
2025-12-17 15:09:28
CNS Pharmaceuticals' shares saw a dip following the announcement of its CEO's departure. The market reacted to this leadership change, impacting the company's stock value. This development suggests investor uncertainty regarding the company's future direction.
